Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 6/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.38 |
| ▸ | CDK1 | P06493 | 5/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076100 | 0.81 | AHR (0.43) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL8545481 | 0.78 | AHR (0.49) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL31414332 | 0.78 | AHR (0.49) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL19235316 | 0.78 | AHR (0.41) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL18289479 | 0.77 | AHR (0.50) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL261277 | 0.73 | AHR (0.48) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL29622013 | 0.73 | AHR (0.48) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL6970909 | 0.73 | GSK3B (0.40) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL12064441 | 0.71 | DRD2 (0.44) | AHRCMA1GSK3BCCNB2CDK1 | |
| SCHEMBL4409544 | 0.70 | CCNB2 (0.38) | AHRCMA1GSK3BCCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1147486-C | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles | - | 2004-04-28 | — | — | CN | claimed |
| CN-1138773-C | 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 | - | 2004-02-18 | — | — | CN | claimed |
| EP-1157019-B1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | HOFFMANN LA ROCHE (CH) | 2003-03-19 | — | — | EP | claimed |
| CN-1331689-A | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | claimed |
| CN-1330647-A | 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | claimed |
| US-6313310-B1 | JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | claimed |
| US-6303793-B1 | INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-10-16 | — | — | US | claimed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-6313310-B1 | JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1149092-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6307056-B1 | INHIBIT OR MODULATE PROTEIN KINASES, IN PARTICULAR JNK PROTEIN KINASES. | HOFFMAN-LA ROCHE INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303793-B1 | INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6252086-B1 | CYCLIN-DEPENDENT KINASES INHIBITORS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2001-06-26 | — | — | US | disclosed |
| US-6130239-A | INHIBIT CYCLIN-DEPENDENT KINASES | HOFFMANN-LA ROCHE INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000035906-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | PRKACA, PACSIN2, PRKACB | AHR 4803/4885CMA1 800/4885GSK3B 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.